Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Combined treatment of HCV infection: is there a need for meta-analysis?
Autore:
Bacosi, M; Patsouri, M; Miglioresi, L; Patrizi, F; Russo, F; Ricci, GL;
Indirizzi:
Policlin Univ Rome La Sapienza, Dept Clin Sci, Gastroenterol Unit, Rome, Italy Policlin Univ Rome La Sapienza Rome Italy stroenterol Unit, Rome, Italy
Titolo Testata:
HEPATOLOGY RESEARCH
fascicolo: 3, volume: 20, anno: 2001,
pagine: 359 - 371
SICI:
1386-6346(200107)20:3<359:CTOHII>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHRONIC HEPATITIS-C; PLUS RIBAVIRIN; RANDOMIZED TRIAL; INTERFERON-ALFA; COMBINATION; THERAPY; METAANALYSIS; RETREATMENT; PLACEBO; VIRUS;
Keywords:
interferon; ribavirin; HCV;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Ricci, GL Policlin Univ Rome La Sapienza, Dept Clin Sci, Gastroenterol Unit, Piazzale Aldo Moro 5, Rome, Italy Policlin Univ Rome La Sapienza Piazzale Aldo Moro 5 Rome Italy
Citazione:
M. Bacosi et al., "Combined treatment of HCV infection: is there a need for meta-analysis?", HEPATOL RES, 20(3), 2001, pp. 359-371

Abstract

Background/Aims. The aim of this study was to estabilish the 'true' therapeutical gain of a combined therapy interferon - ribavirin versus interferonmonotherapy in hepatitis C virus infection. Methods. A systematic review of published trials comparing combined treatment (interferon + ribavirin) vs interferon monotherapy, was performed on articles printed from 1991 to 1999. Results. The meta-analysis of retrieved trials showed that ribavirin significantly enhances the sustained response rate to interferon therapy in all types of patients. The results of almost all studies were homogeneous: combined therapy approximately doubles response rates compared to interferon monotherapy. At the end of the treatment, ribavirin increased the rate of viral clearance approximately 22% and the biochemical response of about 31%. The net gain was about 24% for both viral and biochemical response rate after 24 weeks of follow-up. Conclusion. Combined therapy showed a significantly higher efficacy in terms of sustained negativity of viral genome in all classes of patients (naives, relapsers, non-responders) becoming the therapy of choice. Nevertheless, more than about 50% of patients infected by hepatitis C virus show no sustained response to treatment. The whole weight of final data is beared by the major trials all with similar results, (C) 2000 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 20:23:29